Rescheduling Opens a New Door for Cannabis Trademarks and Patents

Photo by litoon dev via Unsplash.

For years, the phrase "cannabis trademark" was almost a contradiction in terms at the federal level -- the kind of application an IP attorney would file only to watch it die in examination. That changed, at least partially, on April 28, 2026, when a final order from Acting Attorney General Todd Blanche moved marijuana from Schedule I to Schedule III of the Controlled Substances Act. But the shift wasn't the blanket legalization some in the industry had hoped for. It applies to exactly two categories: marijuana used in FDA-approved drug products, and marijuana handled under a state medical marijuana license. Everything else -- meaning nearly all the recreational and adult-use product that actually generates industry revenue -- stays put on Schedule I.

Narrow as it is, the change has already set off a scramble. Companies like Connected International Inc. have filed federal trademark applications in recent weeks that would have looked like wasted legal fees a year ago. Attorneys who spent a decade telling cannabis clients not to bother with the U.S. Patent and Trademark Office are now fielding calls asking how fast filings can go in. The bigger prize -- rescheduling that covers all marijuana, recreational included -- is still sitting in front of the DEA's administrative process, with no fixed date for a ruling. What's happened so far isn't the finish line. It's the moment the ground started moving, and IP lawyers are treating it exactly that way: a real strategic inflection point, not a completed transformation.

What Actually Changed on April 28, 2026

Photo by Katie Moum via Unsplash.

The order that took effect April 28, 2026 is precise almost to the point of being clinical. It reclassifies marijuana from Schedule I to Schedule III, but only where the marijuana in question is either an ingredient in an FDA-approved drug product or is being handled under a state-issued medical marijuana license. That's it. Marijuana sold through adult-use dispensaries, grown by recreational cultivators, or moved through the ordinary commercial channels most of the industry relies on remains fully Schedule I, unchanged by this order. Synthetically derived THC -- the backbone of a lot of popular vape cartridges and edibles -- also stays Schedule I, which means a meaningful slice of current product formulations doesn't benefit from the reclassification at all.

The broader question -- whether to reschedule marijuana as a whole, not just these two carved-out uses -- is being handled separately, through a DEA administrative hearing that ran June 29 through July 15, 2026 in front of Chief Administrative Law Judge Derek C. Julius. Post-hearing briefs were due August 17, and there's no announced timeline for when Judge Julius, or DEA leadership above him, will issue a final decision. Seven outside parties weighed in against full rescheduling, including the National District Attorneys and Sheriffs Association, Smart Approaches to Marijuana, and the states of Nebraska, Idaho, Indiana and Louisiana -- while DEA itself has argued in favor of moving forward. Layer on top of that a set of separate state lawsuits challenging the underlying order, and you've got a regulatory picture that's shifted, but far from settled.

Why Trademarks Were Off Limits for So Long

Photo by Dad Grass via Pexels.

To understand why the April order matters at all for branding, it helps to remember why the USPTO wouldn't touch cannabis marks in the first place. Federal trademark law requires an applicant to show lawful use in commerce, and for as long as marijuana sat on Schedule I, that was structurally impossible -- you can't lawfully sell something federally classified as having no accepted medical use and a high potential for abuse. Examiners refused cannabis-related applications almost reflexively, regardless of how compliant the business was under state law.

Schedule III status chips away at that logic, at least for the two categories the April order covers. If a product is no longer federally prohibited, the argument that its sale can't be lawful use in commerce gets a lot weaker. That's exactly the reasoning behind the recent uptick in filings -- Connected International Inc. among them -- submitting trademark applications tied to state-licensed medical marijuana products in a way that would have been almost pointless to attempt in 2024 or early 2025.

But there's a real gap between a legal theory becoming plausible and an agency actually acting on it. The USPTO hasn't published updated examination guidelines reflecting Schedule III status, which means examiners are working without a clear rulebook for how to treat these applications. Approval isn't automatic, and it isn't guaranteed. And for the recreational and adult-use products that make up the bulk of dispensary sales nationwide, none of this applies -- those goods are still Schedule I, and federal trademark registration for them remains off the table.

The Interstate Commerce Snag Nobody's Solved

Photo by ELEVATE via Pexels.

Even where Schedule III status clearly applies, there's a separate hurdle that rescheduling doesn't touch: interstate commerce. Federal trademark registration doesn't just require that a product be lawful under the Controlled Substances Act -- it requires proof of lawful use in interstate commerce specifically. That's a distinct legal test, and it's one cannabis businesses have struggled with for years precisely because of how legalization has unfolded state by state.

Rescheduling doesn't change the underlying reality that state-licensed marijuana, medical or otherwise, generally can't legally cross state lines. A dispensary in Colorado can't ship product to a customer in New Mexico, no matter what schedule the drug sits on federally, because state licensing regimes are built around in-state, closed-loop supply chains. That means a company operating in only one state -- which describes most licensed cannabis operators -- may still get turned away by the USPTO even for a medical marijuana product that technically now qualifies for Schedule III treatment, simply because it can't demonstrate the interstate commerce that trademark law demands.

This is the piece of the puzzle nobody has solved yet, and it's not clear the April order was ever meant to solve it. Attorneys following the space expect the USPTO will eventually need to issue clearer guidance on how a company's DEA registration and state licensing status intersect with the interstate commerce requirement -- multi-state operators with common ownership structures may have an easier path than single-state license holders, but that's an assumption, not a settled rule. Until the agency weighs in directly, applicants are left interpreting statutory requirements that were written decades before anyone anticipated a state-by-state cannabis market.

Patents: The Quietly Bigger Opportunity

Photo by CDC via Unsplash.

While trademark attorneys have spent the past few months untangling scheduling categories and interstate commerce doctrine, patent attorneys have mostly been watching from the sidelines -- because their corner of IP law never had the same roadblock to begin with. The USPTO's lawful-use-in-commerce requirement, the one that kept cannabis trademarks locked out for decades, simply doesn't apply to patents. A patent protects an invention, not a commercial use of a mark, so Schedule I status was never a categorical bar to patenting cannabis-related innovations.

That's meant cannabis genetics, novel extraction processes, unique formulations, and specific cultivation techniques have been eligible for patent protection all along, regardless of what schedule the plant sat on. Companies that recognized this early built out patent portfolios years before rescheduling was ever seriously discussed, and those filings have held up.

Rescheduling still matters here, just indirectly. As Schedule III status brings more companies, more capital, and more confidence into the space, expect R&D spending to climb and patent filings to climb with it -- new genetics, better extraction efficiency, novel delivery formats. It's less a legal unlock than an economic one. For that reason, several industry attorneys are now pointing to patents, rather than trademarks, as the IP category with the least ambiguity for cannabis businesses to invest in right now. The legal path was never blocked to begin with, which makes it a comparatively stable bet next to a trademark landscape still waiting on the USPTO to write the rules.

What Comes Next for Brands and Filers

Photo by Sora Shimazaki via Pexels.

The immediate risk on the trademark side is a filing surge that outpaces the agency's ability to process it. Attorneys are already warning of something close to a land grab -- companies racing to lock down marks tied to medical marijuana products before competitors do, which could bog down USPTO examination times across the board, cannabis-related or not.

Before that surge turns into approvals at any real scale, the USPTO still needs to publish examination guidelines that actually reflect Schedule III status for the two narrow categories the April order covers. Right now examiners are effectively improvising. There's also an unresolved question about brands that straddle medical and recreational lines -- a company selling an identical product under one name to both medical patients and recreational customers may find itself only partially protected, registered for the medical use but exposed on the recreational side.

For businesses weighing whether to file now, the practical advice is unglamorous but important: confirm exactly how your state's medical marijuana licensing program is structured, verify your product actually falls into one of the two qualifying categories, and talk to an IP attorney before submitting anything. Eligibility here turns on specific product classification, not on general industry legality. And nobody should assume the bigger shift -- full rescheduling covering all marijuana -- is close. The DEA's administrative process remains open-ended, with no announced decision date, which means recreational brands banking on imminent federal trademark access could be waiting considerably longer than they'd like.

Strip away the headlines and what happened on April 28 is a real but narrow legal change, one that rewards companies already working inside FDA-approved drug channels or state medical marijuana programs. It does nothing for the recreational and adult-use market that accounts for most of the industry's actual revenue, and it doesn't resolve the interstate commerce problem that's dogged cannabis trademark applicants for years regardless of scheduling.

Given all that, patents look like the sturdier bet for companies trying to protect their innovations right now. There was never a lawful-use hurdle blocking cannabis patents the way there was for trademarks, so that path hasn't gotten murkier or clearer with rescheduling -- it's just been quietly available the whole time, waiting for more companies to use it.

Brands filing trademark applications today are, in effect, placing a bet on where the DEA's broader rescheduling process ends up -- and on a timeline nobody can currently predict. That bet might pay off. But between an open administrative hearing, pending state lawsuits, and a USPTO that hasn't even finished writing the rules for the narrow slice of marijuana that's already rescheduled, the companies moving fastest right now are also the ones most exposed if the full picture takes another two or three years to resolve.